Development of diabetes mellitus during etanercept therapy in a child withsystemic-onset juvenile rheumatoid arthritis

Although clinical trials of etanercept in adult and juvenile rheumatoid art hritis have generally revealed few adverse events, significant concern has arisen over the potential evolution of secondary autoimmune disease due to modulation of tumor necrosis factor. There have been few reports of such di seases developing, and none in children receiving this therapy, Reported he rein is the case of a 7-year-old girl with a S-year history of systemic-ons et juvenile rheumatoid arthritis with a polyarticular course, in whom type 1 diabetes mellitus developed 5 months after the initiation of etanercept t herapy.